ID   UT-OC-2
AC   CVCL_A1QW
SY   UT-OV-2
DR   Wikidata; Q105511652
RX   CelloPub=CLPUB00591;
RX   PubMed=9888470;
RX   PubMed=32487607;
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 29-06-23; Version: 4
//
RX   CelloPub=CLPUB00591;
RA   Seppanen M.;
RT   "Cytokines and gynecological cancer. In vitro effects of cytokines on
RT   ovarian, endometrial and vulvar carcinoma cells.";
RL   Thesis PhD (2000); Tampere University; Tampere; Finland.
//
RX   PubMed=9888470; DOI=10.1038/sj.bjc.6690046; PMCID=PMC2362186;
RA   Engblom P.R., Rantanen V., Kulmala J., Helenius H., Grenman S.E.;
RT   "Additive and supra-additive cytotoxicity of cisplatin-taxane
RT   combinations in ovarian carcinoma cell lines.";
RL   Br. J. Cancer 79:286-292(1999).
//
RX   PubMed=32487607; DOI=10.21873/anticanres.14294;
RA   Kuittinen T.I., Rovio P., Luukkaala T.H., Laurila M., Grenman S.E.,
RA   Kallioniemi A.H., Maenpaa J.U.;
RT   "Paclitaxel, carboplatin and 1,25-D3 inhibit proliferation of ovarian
RT   cancer cells in vitro.";
RL   Anticancer Res. 40:3129-3138(2020).
//